Literature DB >> 9546437

Potential role for wild-type p53 in leukemias with MLL gene translocations.

M D Megonigal1, E F Rappaport, P C Nowell, B J Lange, C A Felix.   

Abstract

We used single-strand conformation polymorphism (SSCP) analysis of p53 exons 4-8 to screen for possible mutations in 25 pediatric de novo leukemias with translocations of the MLL gene at chromosome band 11q23. Of the 25 patients, 21 were infants. Fifteen cases were acute myeloid leukemia (AML), eight were acute lymphoblastic leukemia (ALL), and two cases were biphenotypic. Nineteen cases were studied at diagnosis and six at time of relapse. p53 mutations were absent in all 19 cases studied at the time of diagnosis. The only mutation was a TGC-->TTC transversion (cys-->phe) at codon 141 in exon 5 in a case of infant ALL at relapse that occurred by subclone evolution after MLL gene translocation. We previously showed that p53 mutations are also absent in pediatric treatment-related leukemias with MLL gene translocations. The absence of p53 mutations at initial transformation may suggest that the anti-apoptotic effect of mutant p53 is not important in leukemias with MLL gene translocations. Alternatively, exogenous DNA damage may be the common feature in treatment-related and de novo cases. Since MLL gene translocations may occur through DNA repair and wild-type p53 is central to DNA repair, the absence of p53 mutations raises the possibility that wild-type p53, not mutant p53, may be important in the genesis of leukemias with these translocations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9546437     DOI: 10.1038/sj.onc.1201637

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Functional analysis of the leukemia protein ELL: evidence for a role in the regulation of cell growth and survival.

Authors:  R W Johnstone; M Gerber; T Landewe; A Tollefson; W S Wold; A Shilatifard
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

2.  Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors.

Authors:  M D Megonigal; N K Cheung; E F Rappaport; P C Nowell; R B Wilson; D H Jones; K Addya; D G Leonard; B H Kushner; T M Williams; B J Lange; C A Felix
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 3.  The molecular biology of mixed lineage leukemia.

Authors:  Robert K Slany
Journal:  Haematologica       Date:  2009-06-16       Impact factor: 9.941

4.  Mouse models of human AML accurately predict chemotherapy response.

Authors:  Johannes Zuber; Ina Radtke; Timothy S Pardee; Zhen Zhao; Amy R Rappaport; Weijun Luo; Mila E McCurrach; Miao-Miao Yang; M Eileen Dolan; Scott C Kogan; James R Downing; Scott W Lowe
Journal:  Genes Dev       Date:  2009-04-01       Impact factor: 11.361

5.  Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.

Authors:  Isabel Morgado-Palacin; Amanda Day; Matilde Murga; Vanesa Lafarga; Marta Elena Anton; Anthony Tubbs; Hua Tang Chen; Aysegul Ergan; Rhonda Anderson; Avinash Bhandoola; Kurt G Pike; Bernard Barlaam; Elaine Cadogan; Xi Wang; Andrew J Pierce; Chad Hubbard; Scott A Armstrong; André Nussenzweig; Oscar Fernandez-Capetillo
Journal:  Sci Signal       Date:  2016-09-13       Impact factor: 8.192

6.  Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia.

Authors:  Yasutaka Hayashi; Susumu Goyama; XiaoXiao Liu; Moe Tamura; Shuhei Asada; Yosuke Tanaka; Tomofusa Fukuyama; Mark Wunderlich; Eric O'Brien; Benjamin Mizukawa; Satoshi Yamazaki; Akiko Matsumoto; Satoshi Yamasaki; Tatsuhiro Shibata; Koichi Matsuda; Goro Sashida; Hitoshi Takizawa; Toshio Kitamura
Journal:  Nat Commun       Date:  2019-10-25       Impact factor: 14.919

7.  Acute lymphoblastic leukemia to acute myeloid leukemia: an unusual case report of lineage switching.

Authors:  Sudarshan Pandit; Nilesh Wasekar; Girish Badarkhe; Venkata Ramesh Yasam; Rajnish Nagarkar
Journal:  Hematol Transfus Cell Ther       Date:  2020-07-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.